Streetbeat News

Stock Prices

CVS

TD Cowen analyst Charles Ryhee has maintained an Outperform rating on CVS Health (NYSE:CVS) but has reduced the price target from $102 to $99.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:32 pm

MOR

MorphoSys shares are up following positive results from the Phase 3 MANIFEST-2 study of pelabresib with ruxolitinib in myelofibrosis patients.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:32 pm

AVGO

Broadcom's stock (AVGO) is trading higher following Citigroup's reinstatement of a Buy rating and a new price target of $1,100.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:32 pm

BMEA

Biomea Fusion, Inc. (NASDAQ:BMEA) shares have declined by nearly 40% over the past five days, continuing a downward trend. The company presented clinical data for BMF-219 at the American Society of Hematology Annual Meeting and will detail Phase II study results in March 2024. Despite meaningful HbA1c reductions in patients, the stock has attracted significant short interest, with 44.9% of BMEA shares sold short.

Portfolio Pulse from Erica Kollmann

December 11, 2023 | 4:30 pm

KDP

Over the past 10 years, Keurig Dr Pepper (NASDAQ:KDP) has produced an average annual return of 15.64%, outperforming the market by 5.72% on an annualized basis. A $100 investment in KDP a decade ago would be worth $424.23 today. Keurig Dr Pepper currently has a market capitalization of $45.61 billion.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 4:30 pm

CNI

Over the past 20 years, Canadian National Railway (NYSE:CNI) has produced an average annual return of 13.13%, outperforming the market by 5.7% annually. A $1000 investment in CNI 20 years ago would now be worth $11,785.30. The company's current market capitalization stands at $76.29 billion.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 4:30 pm

PSTX

Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Poseida Therapeutics (NASDAQ:PSTX) and increased the price target from $8 to $10.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:28 pm

M

Macy's Inc (NYSE:M) shares surged over 15% due to a $5.8 billion buyout offer from Arkhouse Management and Brigade Capital Management, a bullish technical signal (Golden Cross), and recent analyst price target upgrades. The buyout offer at $21 per share is seen as a potential rescue amid competition from e-commerce. The stock's 50-day SMA crossing the 100-day SMA is a positive sign for traders. In November, JPMorgan and Telsey Advisory Group raised their price targets for Macy's stock.

Portfolio Pulse from Surbhi Jain

December 11, 2023 | 4:28 pm

BLUE

B of A Securities analyst Jason Gerberry has maintained a Buy rating on bluebird bio (NASDAQ:BLUE) and increased the price target from $11 to $12. This adjustment reflects a positive outlook on the company's stock, suggesting potential upside from the current trading levels.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:25 pm

PSTX

RHHBY

Poseida Therapeutics Inc (PSTX) reported positive early results from a Phase 1 study of P-BCMA-ALLO1, a CAR-T therapy candidate for multiple myeloma, in partnership with Roche Holdings AG (RHHBY). The study showed an 82% overall response rate, with high rates of partial and complete responses and well-tolerated safety profile. The news has led to a 20.6% increase in PSTX shares in premarket trading.

Portfolio Pulse from Vandana Singh

December 11, 2023 | 4:17 pm